BioUtah Members Can Get Discounted Registration to the 2023 RESI conference
July 13, 2023
BioUtah partnered with Life Science Nation to get you the Super Early Bird prices to the largest early-stage life science partnering conference called Redefining Early-Stage Investments (RESI). RESI takes place across 3-days from September 18th – 20th in a hybrid format. The first day on September 18th is onsite at the Boston Park Plaza Hotel in Massachusetts, USA, with 1-1 partnering meetings, onsite investor panels, workshops, exhibition, and pitch sessions. Followed are two days of virtual 1-1 partnering on September 19th – 20th. See best ticket option for you.Contact Erika Wu e.wu@lifesciencenation.com for any questions.
You can get access to the cocktail reception, partnering (meetings with investors that are a fit for your technology & stage of development) as well as access to all the workshops & investor-led panels, and see how other startup CEOs are successfully delivering their pitches to investors in the Innovator’s Pitch Challenge (IPC). Perfect for startups in Therapeutics, Diagnostics, Digital Health, or Medical Devices who want to raise up anywhere between $25K — $50M USD in capital and/or to find licensing partners.
** If you’re not ready for partnering, but would like to see the format of RESI, please register for the Audience Access Pass (AAP) to get access to all in-person sessions on September 18th, and no partnering.
LSN to offer BioUtah Startups:
- **Audience Access Pass (AAP): $595 > $495 use the discount code “100UTAH“
- 3-day ticket: $1,995 > $1,495 use the discount code “1495UTAH“
- 2-day ticket: $1,195 > $895 use the discount code “895UTAH“
Please note: the RESI partnering platform is open from August 21st – October 13th. Register ASAP to ensure you can have optimal time to identify, conduct outreach, and confirm meetings with investors.
Register Here to get signed up for Hybrid RESI Boston, September 18th – 20th.
For additional information, please refer to the information sheet or visit https://resiconference.com/.
Recent News
- bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
- DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
- 2025 BIO International Recap
- Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
- Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
- RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS